• No results found

Good Clinical Practice (GCP) Course

N/A
N/A
Protected

Academic year: 2021

Share "Good Clinical Practice (GCP) Course"

Copied!
7
0
0

Loading.... (view fulltext now)

Full text

(1)

7th

Good Clinical Practice

(GCP)

Course

21-22 November, 2011

Szeged, Hungary

(2)

Dear Colleagues,

We are pleased to welcome you to Szeged to take part in the 7

th

Good Clinical Practice Course

organized by the Department of Obstetrics and Gynecology at the University of Szeged, and the

Hungarian Clinical Trial Management Society, with the support of the World Health

Organization.

Doctors, researchers and clinical investigators are welcome mainly from our Euroregion. The

first day of the Course will be dedicated to the basic knowledge of the GCP, mainly for

those who are interested in Clinical Trials and are in need of a Certificate. A Valedictory

lecture which will be held on behalf of the WHO, entitled “The involvement of the

transitional countries in Clinical Trials. (Awareness of good clinical practice or

implementation of the guidelines of WHO)”, to share the experience and knowledge of the

WHO accumulated in the field of GCP. The course ends with a test.

For the first time in Szeged/Hungary, on the second day a Biosimilar Symposium will be

held as a hot topic of research on „Bioequivalence, Bioavailibility and Biosimilarity”

by internationally acknowledged clinicians

The 7

th

GCP Course will take place in Szeged. We would like to introduce you the host city, for

those who will attend the first time: Szeged is an exciting University city with a rich cultural life.

It is also famous for exhibitions, ballet and opera performances, and many of beautiful buildings

in secessionist style. Besides, the Hungarian traditional food, such as fish-soup and Pick salami, is

worth trying.

We are certain that everyone will enjoy the 7

th

Good Clinical Practice Course to be held in

Szeged,

On behalf of the organizers,

(3)

Organizers

Department of Obstetrics and Gynecology, University of Szeged, Hungary Director: Professor Attila Pál MD

and

Hungarian Clinical Trial Management Society, Hungary President: Judit Tarnai MD

with the support of the

World Health Organization

Venue of the Course

Residence of the Chamber of Commerce and Industry – Conference Hall Address: H-6721 Szeged, Párizsi krt. 8-12., Hungary

Official language

The official language of the course is English.

Organizing committee

Department of Obstetrics and Gynecology

Address: H-6725 Szeged, Semmelweis str.1., Hungary Phone: +36 62 545 493; Fax: +36 62 545 711 E-mail: [email protected]

Organizing office

STAND-ART Agency Ltd.

Office: H-6723 Szeged, Tisza Palace B/2., Felső Tisza part 31-34. Phone: +36 62 317 445; Fax: +36 62 317 445

E-mail: [email protected]

URL: http://www.standartkonferencia.hu

Accreditation

The CME accreditation is in process.

Accommodation

Accommodation in Szeged should be booked and paid by the participants themselves. You can find information about hotels and pensions here:

http://en.standartkonferencia.hu/Szegedhotel/szallas

Taxi

Rádió Taxi: +36 62 480 480

Parking

Please be advised that in downtown of Szeged there are three different designated parking zones (green, yellow and blue). To park in these zones (indicated on the traffic signs) you will have to obtain a pre-paid parking ticket. This has to be displayed in a well-visible place, possibly behind the windscreen (from Monday to Friday, 8.00-18.00). A daily parking ticket is available for 1.475,- HUF. PLEASE NOTE that your car may be towed if you do not have a valid

ticket! Parking tickets can be bought at grocery stores, tobacconists and newsagents. The congress venue is in the blue

(4)

21 November, 2011 – Monday

PRELIMINARY PROGRAM

08.00 – 08.45 Registration 08.45 – 09.00 Opening ceremony 09.00 – 09.15

Introduction of the Hungarian Clinical Trial Management Society (15’)

Speaker: Judit Tarnai, Country Manager, Pharm-Olam (Hungary) Medical Research Ltd. 09.15 – 09.35

ICH-GCP – history and current position (20’)

Speaker: Szabolcs Barótfi, Quintiles Ltd., Budapest, Hungary 09.35 – 09.55

Role of the regulatory authority (20’)

Speaker: Csilla Pozsgay, National Institute for Quality and Organizational Development in Healthcare and Medicine

09.55 – 10.10

Declaration of Helsinki and the Ethics Committees (15’) Speaker: Dorottya Mogyorósi, Ministry of National Resources 10.10 – 10.30

Human Drug Development: Phases and Methods (20’) Speaker: Gábor Renczes, GXP Ltd.

10.30 – 10.40

Panel I discussion (10’) 10.40 – 11.00

Coffee break 11.00 – 11.20

ICH guidelines and the Non-interventional trials (20’) Speaker: László Veres, Covance Ltd., Budapest, Hungary 11.20 – 11.40

Main Operational Issues of Clinical Trials I.: Site Selection and Site Initiation Process (20’) Speaker: Krisztina Köböl, Pharm-Olam (Hungary) Medical Research Ltd.

11.40 – 12.00

Main Operational Issues of Clinical Trials II.: Interim Monitoring Procedures + Informed consent development (20’)

Speaker: Norbert Szakolczai-Sándor, Theorem Clinical Research Ltd. 12.00 – 12.20

Main Operational Issues of Clinical Trials III.: Close-down Procedures, The Trial Master File (20’)

Speaker: Gábor Szamosközi, Novartis Pharma Hungary 12.20 – 12.30

Panel II discussion (10’) 12.30 – 13.30

(5)

13.30 – 13.45

Informed Consent Process (15’)

Speaker: János Annus, University of Szeged 13.45 – 14.00

Quality issues/How to prepare for a Successful Audit ? (15’) Speaker: Éva Kállai, Quintiles Hungary Ltd.

14.00 – 14.20

Pharmacovigilance and Reporting Procedures (20’) Speaker: Gábor Koncsik, Servier ICTR Hungary 14.20 – 14.40

The Sponsor’s Role and Responsibilities (20’) Speaker: Géza Szövérffy, MSD Hungary Ltd. 14.40 – 14.55

The Investigator: Role and Responsibilities (15’) Speaker: Tamás Bitó, University of Szeged

14.55 – 15.05

Panel III discussion (10’) 15.05 – 15.25

Coffee break 15.25 – 15.40

The Role of Study Nurse and Study Coordinator (15’) Speaker: Andrea Tiszai, University of Szeged

15.40 – 15.55

Project Management of Clinical Trials (15’) Speaker: Gábor Keszthelyi, I3 Research Ltd. 15.55 – 16.10

Device studies (15’)

Speaker: Eszter Fodor, Pharma Hungary Ltd. 16.10 – 16.25

Emerging Countries (pros and cons) (15’) Speaker: Zsuzsanna Pozsonyi, SynCon International 16.25 – 16.40

Statistics in clinical trials - Essentials for non-statisticians (15’) Speaker: Wouter Wijker, Auxiliis Pharma Ltd., Budapest

16.40 – 16.50

Technical break 16.50 – 17.10

VALEDICTORY LECTURE

The involvement of the transitional countries in Clinical Trials. (Awareness of good clinical practice or implementation of the guidelines of WHO) (20’)

Speaker: Nguyen Thi My Huong, MD, PhD, Clinical Trial Manager, Department of Reproductive Health & Research (RHR), World Health Organization

17.10 – 17.30 GCP test

(6)

22 November, 2011 – Tuesday

BIOSIMILAR SYMPOSIUM

By attending this workshop you will gain a comprehensive outlook on the key issues surrounding biosimilars including manufacturing, non-clinical and clinical development. The regulatory requirements for similars will be presented together with the already existing clinical and market experience in the EU. Session 1 - Chair: Dr. Andras Ballagi

08.30 – 09.05

Dr. Ildiko Aradi: Biosimilars - General overview, regulatory (EU, US and WHO guides) (35’) 09.05 – 09.40

Dr. Andras Ballagi: The development of similar biological medicines (35’) 09.40 – 10.15

Dr. Arnold M. Kiss: Quality requirements - analytics (35’) Discussion (15’)

10.30 – 10.40 Coffee break

Session 2 - Chair: Dr. Ildiko Aradi 10.40 – 11.15

Dr. Ivett Jelinek and Dr. Mark Barok - Non-clinical program of biosimilars - goals and regulations (35’)

11.15 – 11.50

Dr. Alice Rokszin and Dr. Andras Illes: Medical consequences of immunogenicity (35’) 11.50 – 12.25

Dr. Adam Kreiss: Adaptive design (35’) Discussion (15’)

12.40 – 13.30 Lunch break

Session 3 - Chair: Dr. Andras Illes 13.30 – 14.05

Dr. Karoly Horvát-Karajz: Endpoints for clinical trials in oncology (35’) 14.05 – 14.40

Dr. Zsuzsanna Kiss and Dr. Adam Kreiss: Endpoints for clinical trials in Rheumatoid arthritis (35’)

14.40 – 14.50 Coffee break 14.50 – 15.25

Dr. Eniko Jokai and Dr. Andras Illés: Approved biosimilars in the EU - clinical requirements (35’) 15.25 – 16.00

Zsuzsanna Molnar and Dr. Alice Rokszin: Biosimilars in the EU: medical and market experience (35’)

(7)

Discussion (15’) Closing remarks (10’)

References

Related documents

Question: What role does the Guru play in the life and teachings of Ramana Maharshi?. Papaji: The Guru plays the part to teach you once that the Self is within your own Heart and

The University of Debrecen has recently completed a multi-year project towards introducing online courses for students taking ESP across the curriculum. The

The weak-form efficient market hy- pothesis for two oil crude markets (UK Brent and US West Texas Intermediate) is tested with non-parametric variance ratio tests developed by

The main components of the system architecture, as shown in figure 3.1, are end nodes with data collecting equipment and monitoring sensors, multi technology communication, Wi-Fi

(See Introduction to Child Care Subsidy Research for a full explanation of CCDF.) Within the broad group of low-income working families potentially eligible for subsidies,

RECIPROCITY - PERSONAL CERTIFICATES – BROWARD COUNTY The following application was reviewed by the Board and APPROVED: GHEORGHE ORZAGLAVAN (JOURNEYMAN ELECTRICIAN).

Proponents of deregulation argue that competition will lower electric rates, particularly in the regions with high rates, and make them more uniform throughout the nation..

So we have good reason to heed Solon's warning. He was a philosopher, however, and such men are not moved to happi- ness or unhappiness by Fortune's favours or her slights; for